Empresas y finanzas

BIOTECHNICA 2008 Boasts Debut of New Event for Pharmaceutical Biotechnology



    BIOTECHNICA 2008 will be staging the first separate meeting-place
    for pharmaceutical biotechnology. This year´s event will see the debut
    of the new platform "Science to Market" staged by the European
    Association of Pharma Biotechnology (EAPB), which represents joint
    cooperation with European BioPerspectives, a conference organized by
    DECHEMA (Society for Chemical Engineering and Biotechnology). Stephan
    Kuhne, Board member of Deutsche Messe AG, believes: "The collaboration
    with BIOTECHNICA will add considerably to the promotion of research
    projects dedicated to pharmaceutical biotechnology." The President of
    the EAPB, Wieland Wolf, adds: "Science to Market will provide an
    important impetus to the dialogue between science and the business
    community. The event offers European research institutes and
    universities an ideal platform for presenting their R&D efforts and an
    opportunity to establish international contacts with industrial
    companies with a view to promoting potentially commercial products."

    Wieland Wolf explains: "Pharmaceutical biotechnology is becoming
    an important economic factor worldwide. In 2006 innovative
    developments in the therapy, diagnosis and prevention of disease
    produced global sales worth 60 billion US dollars. Across the entire
    industry we are seeing annual growth rates of up to twenty percent."
    Therefore the aim of the new platform "Science to Market" is to
    promote and underpin the scientific and research side of European
    pharmaceutical biotechnology.

    "Science to Market" will take place on 7 and 8 October in the
    Convention Center at the Hannover Exhibition Grounds. The focus of the
    two-day conference will be on the application of new biopharmaceutical
    drugs and developments in diagnosis as well as the current technology
    in biopharmaceutical development and manufacture. Keynote themes
    include second-generation biopharmaceuticals, new types of vaccine

    developments in gene therapy, drug formats and methods for improving
    the production and analysis of modern biopharmaceuticals.

    For more details on the events and conference program please
    visit: www.eapb.org.

    Additional press releases and photos may be downloaded from:

    www.biotechnica.de/pressservice